Showing 1981-1990 of 2038 results for "".
- FDA Chief Scott Gottlieb to Resignhttps://modernod.com/news/fda-chief-scott-gottlieb-to-resign/2476349/FDA Commissioner Scott Gottlieb is resigning, ending a tenure at the agency where he approved a flood of new drugs and cheaper copycat pills, and pushed for sharp curbs on e-cigarette use to halt what he called an epidemic of youth use, according to a Bloomberg
- Novartis Issues Summary Financial Information for the Alcon Eye Care Business Ahead of Shareholder Votehttps://modernod.com/news/novartis-issues-summary-financial-information-for-the-alcon-eye-care-business-ahead-of-shareholder-vote/2476260/Novartis today published certain key financial information for the Alcon eye care business covering the full year 2018 ahead of a vote on the proposed 100% spin-off of Alcon at the Novartis Annual General Meeting of Shareholders (AGM) on February 28, 2019. The issuance of the short form fi
- Eyenovia Announces Confirmatory Results from Second MicroStat Phase 3 Registration Study for Mydriasishttps://modernod.com/news/eyenovia-announces-confirmatory-results-from-second-microstat-phase-3-registration-study-for-mydriasis/2476266/Eyenovia announced positive results from its second MicroStat phase 3 study, MIST-2, which examined the safety and efficacy of the company’s first-in-class MicroStat fixed-combination formulation for pharmacologic mydriasis. The MIST-2 study was a US-based, multicenter, randomized, double-
- FDA Approves Bausch + Lomb’s Lotemax SM For The Treatment Of Postoperative Inflammation And Painhttps://modernod.com/news/fda-approves-bausch-lombs-lotemax-sm-for-the-treatment-of-postoperative-inflammation-and-pain/2476267/Bausch + Lomb announced that the FDA has approved Lotemax SM (loteprednol etabonate ophthalmic gel) 0.38%, a new gel formulation for the treatment of postoperative inflammation and pain following ocular surgery. Compared to Lotemax Gel 0.5%, Lotemax SM delivers a submicron particle size for faste
- Bausch + Lomb Acquires Eton Pharmaceuticals’ EM-100 Investigational OTC Eye Drop For Allergic Conjunctivitishttps://modernod.com/news/bausch-health-acquires-eton-pharmaceuticals-em-100-investigational-eye-drop-for-the-treatment-of-itchy-eyes-associated-with-allergies/2476282/Bausch Health Companies’ subsidiary Bausch + Lomb has acquired the US rights to Eton Pharmaceuticals’ investigational eye drop EM-100. If approved, the eye drop will be the first over-the-counter preservative-free formulation eye drop for the treatment of ocular itching associated wit
- Leiters and Mobius Therapeutics Enter into National Sales and Marketing Agreement for Mitosolhttps://modernod.com/news/leiters-and-mobius-therapeutics-enter-into-national-sales-and-marketing-agreement-for-mitosol/2476290/Leiters and Mobius Therapeutics announced that they have entered into a national sales and marketing agreement for Mitosol, the only FDA approved formulation of mitomycin-c bearing an ophthalmic indication. Leiters, an FDA-registered 503B outsourcing provider
- Laser Vision Correction Market Growth Continues for Third Consecutive Yearhttps://modernod.com/news/laser-vision-correction-market-growth-continues-for-third-consecutive-year/2476315/US laser vision correction procedure volume grew for the third straight year in 2018, reflecting continued strong demand for LASIK and other forms of laser vision correction, according to figures released by The Refra
- USPSTF Reaffirms Advice on Prevention of Gonococcal Eye Infections in Newbornshttps://modernod.com/news/uspstf-reaffirms-advice-on-prevention-of-gonococcal-eye-infections-in-newborns/2476334/The U.S. Preventive Services Task Force (USPSTF) continues to recommend that all newborns be treated with a topical antibiotic ointment to prevent gonococcal eye infections, according to a Reuters report. This “A” recom
- Founders of The Lens Butler Announce Boxsee, a New Contact Lens Subscription Servicehttps://modernod.com/news/founders-of-the-lens-butler-announce-boxsee-a-new-contact-lens-subscription-service/2476342/Beth Samenuk and Allison Granger, formerly of The Lens Butler, announced their new company and brand, Boxsee. The company represents a new vision for the future of their partnered contact lens subscription service and increases their o
- Lutronic Vision Initiates Preclinical Trial of R:GEN Laser for the Treatment of Dry AMDhttps://modernod.com/news/lutronic-vision-initiates-preclinical-trial-of-rgen-laser-for-the-treatment-of-dry-amd/2476343/Lutronic Vision announced that it has initiated a preclinical trial to determine the optimal setting for its R:GEN laser for the treatment of the dry form of age-related macular degeneration (AMD). This study has been initiated at the University of Southern California with Stan Louie, PharmD, Pr